140 related articles for article (PubMed ID: 25004227)
1. Public biotech 2013--the numbers.
Lawrence S; Lahteenmaki R
Nat Biotechnol; 2014 Jul; 32(7):626-32. PubMed ID: 25004227
[No Abstract] [Full Text] [Related]
2. Public biotech 2009-the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
[No Abstract] [Full Text] [Related]
3. Public biotech 2007--the numbers.
Lawrence S; Lähteenmäki R
Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
[TBL] [Abstract][Full Text] [Related]
4. Biotech financing retrenches in Q2.
Lawrence S
Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
[No Abstract] [Full Text] [Related]
5. 2007--a banner year for biotech.
Lawrence S
Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
[No Abstract] [Full Text] [Related]
6. 2005: biotech partners up.
Lawrence S
Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145
[No Abstract] [Full Text] [Related]
7. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
8. Biotech on pace for record year.
Yang W
Nat Biotechnol; 2011 Sep; 29(9):780. PubMed ID: 21904312
[No Abstract] [Full Text] [Related]
9. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
10. Public biotech 2011--the numbers.
Huggett B; Lähteenmaki R
Nat Biotechnol; 2012 Aug; 30(8):751-7. PubMed ID: 22871710
[No Abstract] [Full Text] [Related]
11. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
12. Biotech's wellspring: the health of private biotech in 2012.
Huggett B
Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
[No Abstract] [Full Text] [Related]
13. 2006: a stellar year for financing.
Lawrence S
Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
[No Abstract] [Full Text] [Related]
14. Upward trend in financing continues, but fewer feel flush.
Lawrence S
Nat Biotechnol; 2007 Jan; 25(1):3. PubMed ID: 17211374
[No Abstract] [Full Text] [Related]
15. Public companies get creative in raising finance.
Hodgson J
Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
[No Abstract] [Full Text] [Related]
16. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
17. IPOs break $1 billion in Q2.
Lawrence S
Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
[No Abstract] [Full Text] [Related]
18. Korean biotechs seize opportunity to list on public markets.
Louët S
Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
[No Abstract] [Full Text] [Related]
19. Public markets show signs of life.
Mitchell P
Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
[No Abstract] [Full Text] [Related]
20. The rise of European venture capital for biotechnology.
Howell M; Trull M; Dibner MD
Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
